Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED

Ling Li1, Hailong Zhang1, Man Zhang1

  • 1China Novartis Institutes for BioMedical Research, Shanghai, China.

Plos One
|January 11, 2017
PubMed

Insights

Researchers identified new Polycomb repressive complex 2 (PRC2) inhibitors that bind to the EED protein. Structural analysis reveals a common deep pocket formed by compound binding, offering insights for developing novel cancer therapies targeting PRC2.

Area of Science:

  • Epigenetics
  • Structural Biology
  • Drug Discovery

Background:

  • Polycomb repressive complex 2 (PRC2) is a key epigenetic regulator and cancer drug target.
  • EED is a regulatory subunit of PRC2, binding H3K27me3 to allosterically stimulate PRC2 activity.
  • Previous work identified EED226 as a PRC2 inhibitor with antitumor activity.

Purpose of the Study:

  • To identify and validate new EED binders as PRC2 inhibitors.
  • To elucidate the structural basis of EED-inhibitor interactions.
  • To provide insights for rational drug design targeting PRC2.

Main Methods:

  • Identification and validation of novel EED binders.
  • X-ray crystallography to determine the structures of EED in complex with five compounds.
  • Analysis of compound-protein interactions and conformational changes.

Main Results:

  • Five new EED binders were identified, including EED162 (parental compound of EED226).
  • Crystal structures revealed a common deep pocket formed by compound binding, induced by conformational rearrangement of aromatic residues (Y365, Y148, F97).
  • All compounds interacted with Arg367, and unique interactions were observed for each compound, highlighting the pocket's dynamic nature.

Conclusions:

  • The identified compounds are potent EED binders with potential as PRC2 inhibitors.
  • The structural insights reveal a druggable deep pocket formed by conformational changes in EED.
  • These findings support the rational design of novel EED binders for PRC2 inhibition in cancer therapy.

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.2K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
4.0K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.1K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
9.9K